Progress on the research of therapeutic options for methicillin-resistant Staphylococcus aureus
YANG Shou-shen1, 3, WANG Jing2, FAN Ke-wei1, 3, YANG Xiao-yan1, 3
1. College of Life Sciences, Longyan University, Longyan 364012, China; 2. College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China; 3. Fujian Provincial Key Laboratory for the Prevention and Control of Animal Infectious Diseases and Biotechnology, Longyan 364012, China
Abstract:The infection rate of methicillin-resistant Staphylococcus aureus (MRSA) is increasing, and it is becoming the first pathogenic bacteria of nosocomial infection in the world. Because of its high infection rate, high death rate and the emergence of multidrug resistant strains, the clinical treatments are facing enormous challenges. This paper presents an overview on therapeutic options for methicillin-resistant Staphylococcus aureus, including antibiotic therapy, bacteriophage therapy and vaccine protection, so as to provide references to clinical treatments for this pathogen.
杨守深, 王晶, 范克伟, 杨小燕. 耐甲氧西林金黄色葡萄球菌感染的治疗研究进展[J]. 中国人兽共患病学报, 2016, 32(12): 1117-1121.
YANG Shou-shen, WANG Jing, FAN Ke-wei, YANG Xiao-yan. Progress on the research of therapeutic options for methicillin-resistant Staphylococcus aureus. Chinese Journal of Zoonoses, 2016, 32(12): 1117-1121.
[1] Deurenberg RH, Stobberingh EE. The evolution of Staphylococcus aureus [J]. Infect Genet Evol, 2008, 8(6): 747-763. doi:10.1016/j.meegid.2008.07.007 [2] European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2013: Annual report of the European antimicrobial resistance surveillance network (EARS-Net) [EB/OL]. [2016-02-01].http://ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=4f55ad51-4aed-4d32-b960-af70113dbb90&ID=1205 [3] Mediavilla JR, Chen L, Mathema B, et al. Global epidemiology of community-associated methicillin resistant Staphylococcus aureus (CA-MRSA)[J]. Curr Opin Microbiol, 2012, 15(5): 588-595. doi:10.1016/j.mib.2012.08.003 [4] Shorr AF, Haque N, Taneja C, et al. Clinical and economic outcomes for patients with health care-associated Staphylococcus aureus pneumonia[J]. J Clin Microbiol, 2010, 48(9): 3258-3262. doi:10.1128/JCM.02529-09 [5] Malizos K, Sarma J, Seaton RA, et al. Daptomycin for the treatment of osteomyelitis and orthopaedic device infections: real-world clinical experience from a European registry[J]. Eur J Clin Microbiol Infect Dis, 2016, 35(1): 111-118. doi:10.1007/s10096-015-2515-6 [6] Guleri A, Utili R, Dohmen P, et al. Daptomycin for the treatment of infective endocarditis: results from European Cubicin○R Outcomes Registry and Experience (EU-CORE)[J]. Infect Dis Ther, 2015, 4(3): 283-296. doi:10.1007/s40121-015-0075-9 [7] Gardete S, Tomasz A. Mechanisms of vancomycin resistance in Staphylococcus aureus [J]. J Clin Invest, 2014, 124(7): 2836-2840. doi:10.1172/JCI68834. [8] Goldrick B. First reported case of VRSA in the United States: An alarming development in microbial resistance[J]. Am J Nurs, 2002, 102(11): 17. [9] Friaes A, Resina C, Manuel V, et al. Epidemiological survey of the first case of vancomycin-resistant Staphylococcus aureus infection in Europe[J]. Epidemiol Infect, 2015, 143(4): 745-748. doi:10.1017/S0950268814001423 [10] Zhu X, Liu C, Gao S, et al. Vancomycin intermediate-resistant Staphylococcus aureus (VISA) isolated from a patient who never received vancomycin treatment[J]. Int J Infect Dis, 2015, 33: 185-190. doi:10.1016/j.ijid.2014.12.038 [11] Saravolatz LD, Pawlak J, Johnson LB. In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates[J]. Clin Infect Dis, 2012, 55(4): 582-586. doi:10.1093/cid/cis492 [12] Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus [J]. Lancet, 2001, 358(9277): 207-208. doi:10.1013/S0140-6736(01)05410-1 [13] Gu B, Kelesidis T, Tsiodras S, et al. The emerging problem of linezolid-resistant Staphylococcus [J]. J Antimicrob Chemother, 2013, 68(1): 4-11. doi:10.1093/jac/dks354 [14] Wang J, Lin DC, Guo XM, et al. Distribution of the multidrug resistance gene cfr in staphylococcus isolates from pigs, workers, and the environment of a hog market and a slaughterhouse in Guangzhou, China[J]. Foodborne Pathog Dis, 2015, 12(7): 598-605. doi:10.1089/fpd.2014.1891 [15] Marty FM, Yeh WW, Wennersten C B, et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis[J]. J Clin Microbiol, 2006, 44(2): 595-597. doi:10.1128/JCM.44.2.595-597.2006 [16] Zhang H, Xiao M, Kong F, et al. A multicentre study of meticillin-resistant Staphylococcus aureus in acute bacterial skin and skin-structure infections in China: susceptibility to ceftaroline and molecular epidemiology[J]. Int J Antimicrob Agents, 2015, 45(4): 347-350. doi:10.1016/j.ijantimicag.2014.12.014 [17] Karlowsky JA, Nichol K, Zhanel GG. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance[J]. Clin Infect Dis, 2015, 61(Suppl 2): 58-68. doi:10.1093/cid/civ534 [18] Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin[J]. Drugs, 2010, 70(7): 859-886. [19] Hashizume H, Sawa R, Harada S, et al. Tripropeptin C blocks the lipid cycle of cell wall biosynthesis by complex formation with undecaprenyl pyrophosphate[J]. Antimicrob Agents Chemother, 2011, 55(8): 3821-3828. doi:10.1128/AAC.00443-11 [20] Koyama N, Inokoshi J, Tomoda H. Anti-infectious agents against MRSA[J]. Molecules, 2012, 18(1): 204-224. doi:10.3390/molecules18010204 [21] Remy JM, Tow-Keogh CA, Mcconnell TS, et al. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus : resistance selection and characterization[J]. J Antimicrob Chemother, 2012, 67(12):2814-2820. doi:10.1093/jac/dks307 [22] Magana M, Ioannidis A, Magiorkinis E, et al. Therapeutic options and emerging alternatives for multidrug resistant staphylococcal infections[J]. Curr Pharm Des, 2015, 21(16): 2058-2072. [23] Capparelli R, Parlato M, Borriello G, et al. Experimental phage therapy against Staphylococcus aureus in mice[J]. Antimicrob Agents Chemother, 2007, 51(8) 2765-2773. doi:10.1128/AAC.01513-06 [24] Gill JJ, Pacan JC, Carson ME, et al. Efficacy and pharmacokinetics of bacteriophage therapy in treatment of subclinical Staphylococcus aureus mastitis in lactating dairy cattle[J]. Antimicrob Agents Chemother, 2006, 50(9):2912-2918. doi:10.1128/AAC.01630-05 [25] Hsieh SE, Lo HH, Chen ST, et al. Wide host range and strong lytic activity of Staphylococcus aureus lytic phage Stau2[J]. Appl Environ Microbiol, 2011, 77(3): 756-761. doi:10.1128/AEM.01848-10 [26] Matsuzaki S, Yasuda M, Nishikawa H, et al. Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11[J]. J Infect Dis, 2003, 187(4): 613-624. [27] Hoshiba H, Uchiyama J, Kato S, et al. Isolation and characterization of a novel Staphylococcus aureus bacteriophage, phiMR25, and its therapeutic potential[J]. Arch Virol, 2010, 155(4): 545-552. doi:10.1007/s00705-010-0623-2 [28] Rhoads DD, Wolcott RD, Kuskowski MA, et al. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial[J]. J Wound Care, 2009, 18(6): 237-238, 240-243. doi:10.1586/eri.11.90 [29] Merabishvili M, Pirnay JP, Verbeken G, et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials[J]. PLoS One, 2009, 4(3): e4944. doi:10.1371/journal.pone.0004944 [30] Kingwell K. Bacteriophage therapies re-enter clinical trials[J]. Nat Rev Drug Discov, 2015, 14(8): 515-516. doi:10.1038/nrd4695 [31] Bubeck WJ, Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia[J]. J Exp Med, 2008, 205(2): 287-294. doi:10.1084/jem.20072208 [32] Kennedy AD, Bubeck WJ, Gardner DJ, et al. Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model[J]. J Infect Dis, 2010, 202(7): 1050-1058. doi:10.1086/656043 [33] Stranger-Jones YK, Bae T, Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus [J]. Proc Natl Acad Sci U S A, 2006, 103(45): 16942-16947. doi:10.1073/pnas.0606863103 [34] Senna JP, Roth DM, Oliveira JS, et al. Protective immune response against methicillin resistant Staphylococcus aureus in a murine model using a DNA vaccine approach[J]. Vaccine, 2003, 21(19/20): 2661-2666. doi:10.1016/S0264-410X(02)00738-7 [35] Kuklin NA, Clark DJ, Secore S, et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model[J]. Infect Immun, 2006, 74(4): 2215-2223. doi:10.1128/IAI.74.4.2215-2223.2006 [36] Weisman LE, Thackray HM, Garcia-Prats JA, et al. Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates[J]. Antimicrob Agents Chemother, 2009, 53(7): 2879-2886. doi:10.1128/AAC.01565-08 [37] Patel M, Kaufman DA. Anti-lipoteichoic acid monoclonal antibody (pagibaximab) studies for the prevention of staphylococcal bloodstream infections in preterm infants[J]. Expert Opin Biol Ther, 2015, 15(4): 595-600. doi:10.1517/14712598.2015.1019857 [38] Bagnoli F, Bertholet S, Grandi G. Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials[J]. Front Cell Infect Microbiol, 2012, 2: 16. doi:10.3389/fcimb.2012.00016 [39] Rozemeijer W, Fink P, Rojas E, et al. Evaluation of approaches to monitor Staphylococcus aureus virulence factor expression during human disease[J]. PLoS One, 2015, 10(2): e116945. doi:10.1371/journal.pone.0116945 [40] Srivastava A, Singh BN, Deepak D, et al. Colostrum hexasaccharide, a novel Staphylococcus aureus quorum-sensing inhibitor[J]. Antimicrob Agents Chemother, 2015, 59(4): 2169-2178. DOI: http://dx.doi.org/10.1128/AAC.03722-14 [41] Lehar SM, Pillow T, Xu M, et al. Novel antibody-antibiotic conjugate eliminates intracellular S. aureus[J]. Nature, 2015, 527(7578): 323-328. doi:10.1038/nature16057